|
Variable
|
Overall population (n = 129)
|
Alive at ICU discharge (n = 85)
|
Deceased at ICU discharge (n = 44)
|
p value
|
|---|
|
Age (yr)
|
69 [59–77]
|
63 [58–73]
|
77 [68–82]
|
< 0.001
|
|
Sex male
|
94 (73%)
|
56 (66%)
|
38 (86%)
|
< 0.01
|
|
BMI (kg m−2)
|
28 [25–31]
|
28 [25–31]
|
28 [25–32]
|
NS
|
|
Immunosuppression
|
9 (7%)
|
4 (5%)
|
5 (11%)
|
NS
|
|
Time between 1st symptoms and ICU admission (day)
|
8 [6–11]
|
9 [6–12]
|
7 [5–10]
|
NS
|
|
Time between 1st RT-PCR and ICU admission (day)
|
1 [0–4]
|
1 [0–4]
|
1 [0–2]
|
NS
|
|
SAPS2
|
39 [32–52]
|
36 [28–46]
|
49 [39–53]
|
< 0.001
|
|
SOFA score at ICU admission
|
4 [2–7]
|
4 [2–6]
|
5 [3–8]
|
< 0.05
|
|
ARDS criteria
|
87 (67%)
|
51 (60%)
|
34 (81%)
|
< 0.05
|
|
Respiratory support
|
< 0.01
|
|
Oxygen or NIV or HFNO only
|
42 (33%)
|
35 (41%)
|
7 (17%)
|
|
IV at any time
|
87 (67%)
|
50 (59%)
|
34 (83%)
|
|
ECMO
|
6 (5%)
|
1 (1%)
|
5 (12%)
|
< 0.05
|
|
Vasopressor at any time
|
86 (67%)
|
50 (59%)
|
34 (81%)
|
< 0.05
|
|
RRT at any time
|
24 (19%)
|
13 (15%)
|
13 (30%)
|
NS
|
|
ICU LOS
|
16 [5–31]
|
17 [5–31]
|
15 [5–31]
|
NS
|
|
Antiviral treatment
|
|
None
|
111 (86%)
|
73 (85%)
|
36 (86%)
|
NS
|
|
Immunoglobulin
|
1 (1%)
|
0 (0%)
|
1 (2%)
| |
|
Lopinavir-ritonavir
|
5 (4%)
|
4 (5%)
|
1 (2%)
|
|
Lopinavir-ritonavir + IFN-β
|
2 (1%)
|
0 (0%)
|
2 (5%)
| |
|
Hydroxychloroquine
|
5 (4%)
|
3 (4%)
|
2 (5%)
| |
|
Remdesivir
|
5 (4%)
|
5 (6%)
|
0 (0%)
| |
- Values are median [1st quartile-3rd quartile] or count (percentage)
- ARDS acute respiratory distress syndrome, BMI body mass index, ECMO extracorporeal membrane oxygenation, HFNO high flow nasal oxygen, ICU intensive care unit, IFN-β interferon β, IV invasive ventilation, LOS length of stay, NS not significant, RRT renal replacement therapy, RT-PCR real-time reverse transcriptase polymerase chain reaction, SAPS2 simplified acute physiology score
